The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Overexpression of CSPalpha Using Viral Vectors in the Striatum of a-Syn 1-120 Transgenic Pre-clinicalModel
Objective/Rationale:
Research data have recently indicated that pathology in Parkinson’s disease (PD) starts at the synapse, the part of the neurons where release of dopamine occurs, dysfunction of... -
Rapid Response Innovation Awards, 2011Role of Striatal-Enriched Protein Tyrosine Phosphatase 61 (STEP61) in Parkinson's Disease
Objective/Rationale:
The Park2 gene product parkin is implicated in both genetic and sporadic forms of Parkinson’s disease (PD). Defective parkin function leads to the accumulation of toxic proteins... -
Target Validation, 2011Pre-clinical Models Specifying Nicotinic Receptor Targets in Parkinson's Disease Neuroprotection
Objective/Rationale:
The scientific community has known since 1959 that tobacco use has apparent protective effects against Parkinson’s disease (PD), and some animal models suggest that this... -
Dyskinesia, 2011The Nur77/RXR Transcriptional Complex as a New Target in L-Dopa-induced Dyskinesia Treatment
Objective/Rationale:
Transcription factors are nuclear proteins that regulate gene expression. They are likely to play an important role in long-term molecular maladaptive processes such as those... -
Dyskinesia, 2011Targeting Serotonin Transporters for the Treatment of L-DOPA-induced Dyskinesia
Objective/Rationale:
Levodopa remains the gold-standard treatment for Parkinson’s disease, unfortunately chronic treatment leads to abnormal involuntary movements known as dyskinesia. In recent years... -
Biomarkers, 2011Identifying Peripheral Inflammatory Markers for Parkinson's Disease with Dementia (PDD)
Objective/Rationale:
Patients with Parkinson’s disease (PD) are at a 5.9 times greater risk of developing dementia than the normal population. The identification of sensitive molecular and cellular...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.